Like the trends of glucose‐lowering medications shown in our study, the use of thiazolidinediones and sulfonylureas, associated with an increased fracture risk,(31, 32) has decreased substantially in persons with T2D in Denmark.(33, 34) Yet, the use of newer medications such as GLP‐1 agonists and SGLT2 inhibitors, which have neutral or even beneficial effects on fracture risk,(35, 36) increased rapidly after their introduction.(33, 34). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.